What this study is
This is single-center cross-sectional mechanistic study in lean and obese children with moderate-severe asthma, followed by a randomized, SHAM-controlled trial of Inspiratory Training (IT). The primary outcome is to describe the contributions of inspiratory muscle dysfunction (IMD) and Small Airway Dysfunction (SAD) to obesity-related versus non-obesity-related asthma. The study will involve training (IT) for 8 weeks at three intensity levels (SHAM, low and high). Target dose: 150 inspirations three times weekly. The population includes 6 to 17-year-old children with moderate to severe asthma and with a body mass index qualifying as normal habitus (BMI 5th to 84th CDC percentile) or obese habitus (≥95th percentile BMI and less than 170% of the 95th CDC percentile). Participants will be involved for 10 weeks. The investigators will use analysis of covariance (ANCOVA) to estimate and test the difference in mean values of baseline measures between obese and non-obese cohorts. Covariates will include age, sex (male/female), race/ethnicity, baseline asthma severity (NAEPP step 2 vs ≥3), and atopy status
What's being tested
- Pro2 - Low Dose - 40% of participant's MIP
Intervention · DEVICE
Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).
- Pro2 - High Dose - 75% of participant's MIP
Intervention · DEVICE
Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).
- Pro2 - SHAM - 15% of participant's MIP
Intervention · DEVICE
Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that participants achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).
Study details
- Sponsor
- Duke University
- Conditions
- Asthma in Children · Obesity · Pediatric Obesity · Pediatric Asthma
- Enrolling
- 76 people
- Starts
- 2024-08-01
- Est. completion
- 2027-10-30
- Design
- Quadruple-blind, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 6 Years – 17 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- 6-17 years of age
- Documented clinician-diagnosed asthma
- Currently requiring 2 or more controller prescriptions to treat disease (i.e. moderate to severe persistent disease)
- Either obese (≥95th percentile BMI and less than 170% of the 95th CDC percentile) or have a normal BMI (BMI 5th to 84th CDC percentile)
You can't join if
- ACT (asthma control test) score <17
- Ever intubated for asthma
- FEV1 < 50% of predicted at enrollment
- Currently pregnant
- Legal guardian unable to consent in English or Spanish
- Any major chronic illness that, in the opinion of the PI, would interfere with participation
- Younger than 6 years of age
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (2)
2 openDuke Health Center Creekstone
Durham, North Carolina, United States
- Jason Lang · Contact919-684-3364jason.lang@duke.edu
RecruitingDuke Healthy Lifestyles Clinic
Durham, North Carolina, United States
- Veronica Carrion, BS · Contact919-704-1523vmp19@duke.edu
Recruiting
Study team
Sponsor
Duke University
Study ID Pro00112858
Principal investigator
Jason Lang, MD
Duke University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.